Lipid lowering for primary prevention
- 10 April 2009
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 373 (9670) , 1152-1155
- https://doi.org/10.1016/s0140-6736(09)60357-3
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The need to test the theories behind the Polypill: rationale behind the Indian Polycap StudyNature Clinical Practice Cardiovascular Medicine, 2008
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Primary Prevention of Cardiovascular Mortality and Events With Statin TreatmentsJournal of the American College of Cardiology, 2008
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic StenosisNew England Journal of Medicine, 2008
- Rosuvastatin in Older Patients with Systolic Heart FailureNew England Journal of Medicine, 2007
- Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular DiseaseAnnals of Internal Medicine, 2006
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- A strategy to reduce cardiovascular disease by more than 80%BMJ, 2003
- Pravastatin and the Development of Diabetes MellitusCirculation, 2001